RDY Other Current Liab from 2010 to 2024

RDY Stock  USD 74.55  0.53  0.72%   
Dr Reddys Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2024. During the period from 2010 to 2024, Dr Reddys Other Current Liabilities regression line of annual values had r-squared of  0 and arithmetic mean of  41,679,363,400. View All Fundamentals
 
Other Current Liabilities  
First Reported
2000-03-31
Previous Quarter
43.5 B
Current Value
46.5 B
Quarterly Volatility
38.6 B
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Dr Reddys financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among RDY main balance sheet or income statement drivers, such as Interest Expense of 1.7 B, Total Revenue of 296.9 B or Gross Profit of 245.1 B, as well as many exotic indicators such as Price To Sales Ratio of 3.48, Dividend Yield of 0.0055 or PTB Ratio of 4.2. RDY financial statements analysis is a perfect complement when working with Dr Reddys Valuation or Volatility modules.
  
This module can also supplement Dr Reddys' financial leverage analysis and stock options assessment as well as various Dr Reddys Technical models . Check out the analysis of Dr Reddys Correlation against competitors.

Latest Dr Reddys' Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Dr Reddys Laboratories over the last few years. It is Dr Reddys' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dr Reddys' overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Very volatile
   Other Current Liab   
       Timeline  

RDY Other Current Liab Regression Statistics

Arithmetic Mean41,679,363,400
Geometric Mean20,205,201,527
Coefficient Of Variation96.41
Mean Deviation23,103,961,520
Median28,859,000,000
Standard Deviation40,182,774,344
Sample Variance1614655354T
Range175.9B
R-Value0.06
Mean Square Error1732771331.8T
R-Squared0
Significance0.83
Slope531,667,332
Total Sum of Squares22605174955.9T

RDY Other Current Liab History

202459 B
202356.2 B
202248.9 B
202141.6 B
202033.5 B
201939.4 B
201827.4 B

About Dr Reddys Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Dr Reddys income statement, its balance sheet, and the statement of cash flows. Dr Reddys investors use historical funamental indicators, such as Dr Reddys's Other Current Liab, to determine how well the company is positioned to perform in the future. Although Dr Reddys investors may use each financial statement separately, they are all related. The changes in Dr Reddys's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Dr Reddys's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Dr Reddys Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Dr Reddys. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities56.2 B59 B

Currently Active Assets on Macroaxis

When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:
Check out the analysis of Dr Reddys Correlation against competitors.
Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for RDY Stock analysis

When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stocks Directory
Find actively traded stocks across global markets
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.103
Dividend Share
40
Earnings Share
3.76
Revenue Per Share
272.4618
Quarterly Revenue Growth
0.066
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.